COGT

Cogent Biosciences Inc

31.96

Oct 29 • 3:59 PM ET -0.27 (-0.84%)

31.96

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: CLDX RLAY ERAS IDYA CELC SNY TNGX INCY RVMD SNDX

| Held by: VTI IWM XBI VB VBR VXF IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT
Market Cap	5.55B
Enterprise Value	5.06B
Income	-377.18M
Sales	0.00M
Book/sh	2.72
Cash/sh	4.57
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	258
IPO	Mar 29, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	11.73
P/C	7.00
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.57
Current Ratio	13.57
Debt/Eq	0.46
LT Debt/Eq	0.46
Option/Short	Yes / Yes

EPS (ttm)	-2.44
EPS next Y	-1.09
EPS next Q	-0.56
EPS this Y	-2.59%
EPS next Y	50.78%
EPS next 5Y	-
EPS past 3/5Y	-2.22% 30.89%
Sales past 3/5Y	- -
EPS Y/Y TTM	4.92%
Sales Y/Y TTM	-
EPS Q/Q	12.21%
Sales Q/Q	-
Earnings	Aug 10 BMO
EPS/Sales Surpr.	3.06% -

Insider Own	10.22%
Insider Trans	-0.26%
Inst Own	103.27%
Inst Trans	3.61%
ROA	-68.00%
ROE	-109.74%
ROIC	-48.66%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.64%
SMA50	-1.70%
SMA200	-10.57%
Trades

Shs Outstand	171.60M
Shs Float	155.83M
Short Float	12.62%
Short Ratio	9.93
Short Interest	19.66M
52W High	43.73 -26.92%
52W Low	13.78 131.93%
Volatility	3.64% 4.11%
ATR (14)	1.24
RSI (14)	53.85
Beta	0.35
Rel Volume	0.77
Avg Volume	1.98M
Volume	1,515,556

Perf Week	2.08%
Perf Month	-0.19%
Perf Quarter	-17.90%
Perf Half Y	-10.70%
Perf YTD	-10.02%
Perf Year	99.75%
Perf 3Y	288.34%
Perf 5Y	276.89%
Perf 10Y	-
Recom	1.17
Target Price	55.82
Prev Close	32.23
Price	31.96
Change %	-0.84%

Consensus

Strong Buy

Avg. Price Target

$55.82

Implied Upside

+74.7%

Analysts13incl. previous ratings

Rating Distribution11 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Mar 16, 2026	Resumed	JJefferies	Buy
Nov 10, 2025	Upgrade	WWedbush	Neutral → Outperform	$38	+18.9%
Nov 10, 2025	Upgrade	SStifel	Hold → Buy	$40	+25.2%
Oct 16, 2025	Initiated	SStifel	Hold	$16	-49.9%
Sep 03, 2025	Initiated	RRaymond James	Strong Buy	$30	-6.1%
Mar 07, 2025	Initiated	BScotiabank	Sector Outperform	$17	-46.8%
Dec 11, 2024	Downgrade	NNeedham	Buy → Hold
Feb 26, 2024	Downgrade	RRobert W. Baird	Outperform → Neutral	$14 → $8	-75.0%
Feb 08, 2024	Initiated	CCitigroup	Buy	$11	-65.6%
Dec 11, 2023	Downgrade	WWedbush	Outperform → Neutral	$5	-84.4%
Dec 08, 2023	Initiated	JJP Morgan	Overweight	$18	-43.7%
Apr 28, 2023	Initiated	RRobert W. Baird	Outperform	$20	-37.4%
Mar 27, 2023	Resumed	HH.C. Wainwright	Buy	$28	-12.4%
Dec 14, 2022	Initiated	NNeedham	Buy	$24	-24.9%
Jun 28, 2022	Initiated	GGuggenheim	Buy	$15	-53.1%
Oct 11, 2021	Initiated	HH.C. Wainwright	Buy	$25	-21.8%
Jun 09, 2021	Resumed	JJefferies	Buy	$20	-37.4%
Dec 23, 2020	Initiated	PPiper Sandler	Overweight	$22	-31.2%
Oct 14, 2020	Initiated	LLadenburg Thalmann	Buy	$4	-87.5%

Oct-27-26 04:01PM	Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
Sep-15-26 08:00AM	Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Aug-10-26 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results (GlobeNewswire)
Jun-30-26 08:00AM	Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Jun-12-26 08:01AM	Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress (GlobeNewswire)
08:00AM	Loading…
08:00AM	Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress (GlobeNewswire)
May-30-26 08:00AM	Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-28-26 08:00AM	Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST (GlobeNewswire)
May-27-26 08:00AM	Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 09:30AM	Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress (GlobeNewswire)
May-05-26 08:00AM	Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results (GlobeNewswire)
Apr-21-26 08:00AM	Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-17-26 08:00AM	Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire)
Apr-10-26 05:28PM	Southwest Airlines, Colliers International, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-01-26 08:00AM	Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire) -8.44%
03:59PM	Loading…
Mar-30-26 03:59PM	Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts (Proactive)
Mar-16-26 08:00AM	Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) (GlobeNewswire)
Mar-02-26 02:57AM	Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval (Insider Monkey)
Feb-28-26 09:45AM	Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting (GlobeNewswire)
Feb-27-26 04:06PM	Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval (Insider Monkey)
Feb-17-26 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-10-26 08:00AM	Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting (GlobeNewswire)
Feb-02-26 04:17AM	Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD) (Insider Monkey) +5.71%
Jan-30-26 07:39PM	Elastic NV, Acadia Healthcare, and More Stocks See Action From Activist Investors (Barrons.com)
Jan-27-26 08:06AM	Cogent Biosciences announcse U.S. BTD for bezuclastinib (TipRanks)
Jan-26-26 10:06AM	Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag (Benzinga)
08:00AM	Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
Jan-20-26 08:00AM	Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) (GlobeNewswire)
Jan-12-26 08:00AM	Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio (GlobeNewswire)
Jan-11-26 01:05AM	H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) (Insider Monkey)
08:00AM	Loading…
Jan-06-26 08:00AM	Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 11:37AM	Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day. (Barrons.com)
Dec-30-25 08:00AM	Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis (GlobeNewswire)
Dec-28-25 10:05AM	JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update (Insider Monkey)
Dec-11-25 08:24PM	Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank (Zacks) +5.17%
Dec-08-25 07:30AM	Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Dec-06-25 09:30AM	Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) (GlobeNewswire)
Nov-23-25 07:02AM	Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So (Insider Monkey)
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
Nov-16-25 11:16AM	Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress (Insider Monkey)
Nov-14-25 08:00AM	Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire)
Nov-12-25 05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive) +5.51%
Nov-11-25 11:16PM	Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 (GlobeNewswire)
12:49PM	Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial (Insider Monkey)
Nov-10-25 04:01PM	Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock (GlobeNewswire) +119.03%
01:48PM	Cogent Biosciences Stock Surges 136%. Investors See Promise in Its Cancer Drug. (Barrons.com)
10:45AM	Cogent Biosciences Stock Surges 127%. Why Investors See Promise in Its Cancer Drug. (Barrons.com)
10:43AM	Cogent Biosciences Hits 7-Year High, Up 120% On Its New Stomach Cancer Promise (Investor's Business Daily)
07:00AM	Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
06:14AM	Stock Market Today: Nasdaq, S&P 500, Russell Jump Over 1% As Tech Rebound, Government Reopening Infuses Optimism into Markets (TheStreet)
Nov-03-25 09:01AM	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results (GlobeNewswire)
09:00AM	Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting (GlobeNewswire)
Oct-24-25 12:30PM	Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-20-25 08:32AM	Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib (GlobeNewswire)
Sep-29-25 04:05PM	Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-25 12:59PM	Cogent, Dime added to Raymond James analyst favorites list (Investing.com)
Aug-26-25 08:00AM	Cogent Biosciences Announces Participation in the Citi Biopharma Conference (GlobeNewswire)
Aug-05-25 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results (GlobeNewswire) -5.73%
Jul-31-25 05:31PM	KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 \| DelveInsight (PR Newswire)
Jul-24-25 11:47PM	Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline (Insider Monkey)
Jul-18-25 06:19PM	Rocket, TaskUS, Appian, and More Stocks See Action From Activist Investors (Barrons.com)
Jul-16-25 12:23PM	Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating (Insider Monkey)
Jul-10-25 04:01PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jul-08-25 09:36PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock (GlobeNewswire) +6.34%
04:26PM	Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock (GlobeNewswire)
10:54AM	COGT Stock Soars on Phase III Systemic Mastocytosis Study Success (Zacks)
Jul-07-25 07:06AM	Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis (GlobeNewswire) +23.35%
Jun-11-25 08:00AM	Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing (GlobeNewswire)
May-29-25 08:00AM	Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire) +12.91%
May-13-25 09:55AM	Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade (Zacks)
08:50AM	Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now (Insider Monkey)
May-06-25 08:00AM	Cogent Biosciences Reports First Quarter 2025 Financial Results (GlobeNewswire) -15.62%
May-05-25 07:57AM	Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential? (Insider Monkey) -5.11%
Apr-25-25 08:08AM	Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders (GlobeNewswire)
Apr-20-25 06:16AM	Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts (Insider Monkey)
Apr-16-25 10:03AM	Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -12.32%
Apr-09-25 04:28PM	Cogent: Several 2025 Readouts On Deck With Bezuclastinib Advancement (Seeking Alpha) +7.73% -9.87%
Mar-25-25 04:31PM	Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -6.76% -6.23%
Mar-20-25 08:32AM	Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? (Zacks)
Mar-07-25 08:00AM	Cogent Biosciences Announces Participation in the Leerink Healthcare Conference (GlobeNewswire) -5.40%
Feb-27-25 08:00AM	Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients (GlobeNewswire)
Feb-25-25 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -6.30%
Feb-10-25 09:15AM	Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting (GlobeNewswire)
Jan-30-25 08:00AM	Cogent Biosciences to Participate in the Guggenheim Biotech Conference (GlobeNewswire)
Jan-13-25 08:00AM	Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics (GlobeNewswire)
Jan-08-25 08:00AM	Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 07:00AM	Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients (GlobeNewswire) +8.77%
Dec-08-24 12:00PM	Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Nov-05-24 09:00AM	Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting (GlobeNewswire) -15.84%
Oct-23-24 07:00AM	Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-09-24 08:03AM	Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target (Insider Monkey)
Sep-03-24 08:00AM	Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis (GlobeNewswire)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-06-24 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-28-24 09:18AM	Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting (Zacks)
Jun-27-24 08:00AM	Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial (GlobeNewswire)
Jun-14-24 07:30AM	Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) (GlobeNewswire) -6.18%
May-23-24 05:05PM	Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer (GlobeNewswire) -6.72% +9.75%
05:01PM	Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting (GlobeNewswire)
May-07-24 01:52PM	COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024 (InvestorPlace)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Morris Arlene	Director	Aug 27 '26	Option Exercise	5.39	45,510	245,497	45,510	Aug 31 05:01 PM
Morris Arlene	Director	Aug 27 '26	Sale	37.12	45,510	1,689,493	0	Aug 31 05:01 PM
ARLENE MORRIS	Director	Aug 27 '26	Proposed Sale	36.72	45,510	1,671,127		Aug 27 04:17 PM
Fairmount Healthcare Fund II L	Director	Mar 31 '26	Proposed Sale	34.66	7,000,000	242,620,000		Mar 31 09:30 PM
Fairmount Funds Management LLC	Director	Mar 31 '26	Sale	34.66	7,000,000	242,620,000	5,503,418	Mar 31 09:30 PM
Fairmount Funds Management LLC	Director	Jan 22 '26	Sale	36.40	3,500,000	127,400,000	5,503,418	Jan 22 08:09 PM
Fairmount Healthcare Fund II L	Director	Jan 22 '26	Proposed Sale	36.40	3,500,000	127,400,000		Jan 22 08:05 PM
Kearns Evan	Chief Legal Officer	Dec 26 '25	Sale	38.70	65,000	2,515,500	109,398	Dec 30 04:01 PM
Green John L.	Chief Financial Officer	Dec 26 '25	Sale	38.68	77,000	2,978,360	131,834	Dec 30 04:01 PM
Sachs Jessica	Chief Medical Officer	Dec 26 '25	Sale	38.70	82,642	3,198,245	133,938	Dec 30 04:01 PM
Robinson John Edward	Chief Scientific Officer	Dec 26 '25	Sale	38.74	90,000	3,486,600	140,002	Dec 30 04:01 PM
JESSICA SACHS	Officer	Dec 26 '25	Proposed Sale	38.70	82,642	3,198,435		Dec 29 09:27 AM
JOHN ROBINSON	Officer	Dec 26 '25	Proposed Sale	38.74	90,000	3,486,276		Dec 29 09:08 AM
JOHN GREEN	Officer	Dec 26 '25	Proposed Sale	38.68	77,000	2,978,322		Dec 29 09:06 AM
EVAN D KEARNS	Officer	Dec 26 '25	Proposed Sale	38.70	65,000	2,515,175		Dec 29 09:05 AM

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

PresidentMr. Andrew R. Robbins M.B.A.

CPAMr. John L. Green C.A.

Chief Scientific OfficerDr. John Edward Robinson Ph.D.

Chief Medical OfficerDr. Jessica Sachs M.D.

Chief Commercial OfficerMr. Cole Pinnow

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COGT

Cogent Biosciences Inc

Upgrade your Finviz experience